Key Takeaways
- Base-effect boosted quarter, not a new run-rate: Asia branded generics grew 45% and Africa branded generics grew 34%, but both were elevated by a COVID-suppressed Q1 FY22 base; underlying Africa growth was 20–25% and management guides both segments back to mid-teens.
- US generics stuck in low gear without new approvals: The business grew just 6% with no new launches, and management expects only flattish to low-single-digit growth for FY23 unless the FDA inspects and clears four pending products.
- Margin compressed by one-off and sticky costs: EBITDA margin fell to 23%, hit by a 2% one-time inventory write-off, raw material inflation, US price erosion, and a Rs. 14 Crore freight headwind; management guided FY23 EBITDA at 25–26%, down from earlier 26–27%.
- The US pipeline is the swing factor: Four ANDAs are review-complete and awaiting only an FDA inspection; if the inspection happens in time, launches could begin in Q3, adding both revenue and margin.
- What to watch next quarter: Whether the FDA schedules the plant inspection, the pace of raw material and freight cost normalization, and how much of the Q1 India growth surge reverses as the base normalizes.
US Generics: The Inspection Gate
- Current-state growth is anaemic: Without new product launches, the US business is expected to grow only 4–6% in FY23, constrained by the absence of fresh approvals and the lingering effect of 15–18% price erosion from the prior year.
- Price erosion is normalizing, not reversing: Management believes hyper-competitive behaviour has cooled as competitors realize aggressive share grabs hurt everyone; it estimates erosion returning to the historical 5–8% range, but no price recovery is built into the outlook.
- Four products are stuck at the inspection stage: The FDA has confirmed review is complete on four ANDAs, but approval cannot come until a facility inspection occurs; management has no visibility on timing and says launches could land in Q3 if the inspection happens soon, or slip to Q4 if it is delayed by a quarter.
- Topiramate adds another layer of uncertainty: The product has tentative approval but remains tied up in litigation, and management could not provide a launch date or settlement status on the call, deferring to a later follow-up.
- Chantix offers no near-term relief: The filing is still under FDA review and is not linked to the plant inspection; management sees no visibility for at least a quarter or two and described the timeline as a waiting game.
Yogesh Agrawal: "We have some good products, unfortunately the approvals were lost, now hopefully the inspection starts, so yes we have some good products, which we have already filed and there are some good products which are at advanced stage of filing during the current year also. So they all can bring good value to the company."
Branded Generics: Asia & Africa
- Q1 growth rates overstate the underlying trend: Asia branded generics grew 45% and Africa branded generics grew 34%, but both were measured against Q1 FY22, which was the delta-wave quarter when operations came to a standstill; management confirmed the surge was not channel filling.
- Underlying Africa growth was still strong: Stripping out the base effect, Africa branded generics would have grown 20–25% or higher, driven by market share gains from existing products, new launches, and sales force expansion of roughly 8% YoY.
- Guidance resets to mid-teens for both regions: Management expects growth to settle back to mid-teens going forward, consistent with the long-term trajectory of a business that has delivered steady, non-lumpy expansion across Franco and Anglo Africa.
- The branded-generic export model gives pricing control: In every export market, Ajanta selects the products, sets the price, and runs the promotion; the local distributor only handles logistics for a fee, which management calls the structural advantage that drives sustainability and scalability.
Yogesh Agrawal: "All our brand generic business in the exports also they are all driven by us. So we decide the product, we decide the price, we decide the promotion. Distributor just distributes the product for a cost. So we are able to decide our course of growth, so that is where the beauty is."
India Business: Strong Quarter, Normalizing Ahead
- 22% growth was partly base-driven: Q1 FY22 was disrupted by the second COVID wave, so the exceptional high-double-digit growth this quarter includes a low-base benefit; management expects some of that to come off in Q2 and Q3, which were robust last year.
- Underlying momentum is genuine: India growth exceeded industry rates across all therapies per IQVIA MAT June 2022, the company improved its overall ranking to 28, and it gained one rank each in cardiology and dermatology and two ranks in pain management over the quarter.
- Seven new products launched, two first-to-market: The launch pipeline is concentrated in antidiabetics and cardiology, including fixed-dose combinations, and three brands now appear in the IPM top 500.
- NLEM price increase is flowing through: The company took the full permitted increase on its NLEM portfolio, with the benefit starting to reflect by the end of Q1 and more to come in subsequent quarters.
- Full-year guidance is mid-teens: Management expects India growth to settle at mid-teens for FY23 as the base effect washes out, with trade generics also expected to sustain growth over the next two to three quarters.
Margin Walk & Cost Headwinds
- Raw material cost spiked to 29% versus a 25–26% norm: The overshoot had three components: a 2% one-time inventory write-off from expiry, roughly 1% from raw material and packaging inflation, and roughly 1% from US price erosion flowing through to cost of goods.
- Freight cost added a Rs. 14 Crore drag: Export freight costs have escalated from a pre-COVID level of roughly 6% to 8% of revenue, and management flagged this as the single largest opex headwind beyond raw materials.
- Recovery path is partial and gradual: The 2% inventory write-off will not recur; of the remaining 2% adverse impact, management expects to recover roughly 1% through price increases and INR depreciation over the course of the year.
- FY23 EBITDA guidance trimmed to 25–26%: This is down from an earlier 26–27% range, reflecting the freight and raw material headwinds that are only partly within management's control; any cooling of inflation or freight costs would flow straight to the bottom line.
- Branded-generic investments are a conscious spend choice: Beyond freight and materials, the main opex increase is a deliberate allocation toward the branded generic business, not broad-based cost inflation; management insists cost efficiency on controllable items remains a focus.
Yogesh Agrawal: "I think the industry has understood that this is not helping in fact it is hurting all the companies."
Pipeline, Capex & Capital Allocation
- US ANDA filing pace to accelerate after a slow Q1: Only 1 ANDA was filed and 1 tentative approval received in Q1, but management reiterated the full-year target of 10–12 filings, with activity picking up from Q2 onward.
- R&D spend steady at ~6% of revenue: No change to the investment intensity, with the pipeline weighted toward products that can bring good value once the inspection logjam breaks.
- Full-year capex guided at ~Rs. 200 Crores: This includes maintenance capex; major capacity expansion is already complete, so no large capital outlays are expected in the near future.
- Cash priority is domestic brand acquisitions: Management is actively looking for brand acquisition opportunities in the Indian market and sees no other major use for cash, given that the big capex cycle is behind the company.
- Africa institutional business remains unpredictable: The 44% growth in the quarter is not a trend; this tender-driven business depends on fund availability and procurement agency requirements, and management explicitly declines to guide on it.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India branded business growth | Mid-teens growth for FY23 | FY23 |
| Asia and Africa branded generics growth | Mid-teens growth for both regions | FY23 |
| US generics growth (without new launches) | Flattish to low-single-digit, roughly 4–6% | FY23 |
| US ANDA filings | 10–12 filings, pace picking up from Q2 | FY23 |
| EBITDA margin | 25–26% range | FY23 |
| Raw material cost | Close to 26% going forward | From Q2 FY23 onward |
| R&D spend | ~6% of revenue | FY23 |
| Tax rate | ~21% for FY23, 20–21% next year | FY23 and FY24 |
| Capex | ~Rs. 200 Crores including maintenance | FY23 |
| US price erosion | Normalizing to 5–8% range | Ongoing |
| Four US products awaiting inspection | Launch in Q3 if inspection happens, Q4 if delayed by a quarter | H2 FY23, conditional on FDA inspection |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Total consolidated revenue | ₹951 cr, +27% YoY |
| EBITDA | ₹222 cr, margin at 23% vs 29% YoY |
| PAT | ₹175 cr, +1% YoY; PAT margin at 18% |
| Raw material cost | 29% of revenue, vs guidance of 25–26%; includes 2% one-time inventory write-off |
| R&D expenses | ₹54 cr, 6% of revenue |
| Other income | ₹33 cr, including forex gain of ₹28 cr |
| Income tax rate | 21%, expected to remain at similar level for FY23 |
| Capex incurred | ₹43 cr; full-year FY23 estimate ~₹200 cr |
| India branded generic sales | ₹279 cr, +22% YoY; 30% of total revenue |
| India growth breakup | 7% price increase, 6% volume growth, 3% new product launches |
| India trade generic sales | ₹33 cr, vs ₹27 cr in Q1 FY22 |
| Asia branded generic sales | ₹240 cr, +45% YoY |
| Africa branded generic sales | ₹168 cr, +34% YoY |
| Asia and Africa branded generic exports | ₹408 cr, +41% YoY; 43% of total revenue |
| US generic sales | ₹179 cr, +6% YoY; 19% of total revenue |
| African institution sales | ₹77 cr, +44% YoY; 8% of total revenue |
| US ANDAs awaiting approval | 20 as of end of June 2022; aiming to file 10–12 in FY23 |
| India IQVIA ranking | 28 in June 2022, improved from 29 in March 2022 |
| NLEM portfolio share of India business | ~12% |
| Field force size growth | ~8% YoY |
| EBITDA margin guidance for FY23 | 25–26% |
| India business growth guidance for FY23 | Mid-teens |
| Asia and Africa branded generic business growth guidance | Mid-teens |
| US business growth expectation without new launches | Flattish to low single digit, maybe 5–6% for FY23 |
| US price erosion last year | 15–18% |
| Export freight cost | 8% of revenue, vs ~6% pre-COVID; ~₹14 cr adverse impact in the quarter |